Sugi Predict

Sugi Predict / Compounds / SCHEMBL4154718

SCHEMBL4154718

SCHEMBL4154718

Cn1c(N)cc(=O)n(C)c1=S

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ CYP3A4 P08684 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ CASP6 P55212 1/20 0.38
▸ YTHDF2 Q9Y5A9 1/20 0.33
▸ BRPF1 P55201 1/20 0.33
▸ ATAD2 Q6PL18 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ BACE1 P56817 1/20 0.31
▸ KDM4E B2RXH2 2/20 0.31
▸ NQO2 P16083 1/20 0.31
▸ KDM4A O75164 1/20 0.30
▸ POLB P06746 1/20 0.30
▸ MAPT P10636 1/20 0.30
▸ KDM4C Q9H3R0 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28207015 0.98 ALDH1A1 (0.42) ALDH1A1CYP3A4HPGDCASP6YTHDF2
SCHEMBL23857 0.76 ALDH1A1 (0.55) ALDH1A1CYP3A4HPGDATAD2KDM4E
SCHEMBL28143898 0.74 ALDH1A1 (0.53) ALDH1A1CYP3A4HPGDATAD2KDM4E
SCHEMBL4138900 0.74 HPGD (0.42) ALDH1A1CYP3A4HPGDMAPT
SCHEMBL1963344 0.74 ALDH1A1 (0.71) ALDH1A1CYP3A4HPGDSMN1; SMN2KDM4E
SCHEMBL31416688 0.73 KDM4E (0.31) ALDH1A1CASP6KDM4ENQO2KDM4A
SCHEMBL10836567 0.73 MEN1 (0.33) ALDH1A1CASP6SMN1; SMN2KDM4ENQO2
SCHEMBL13943561 0.73 MAPT (0.33) ALDH1A1CYP3A4HPGDCASP6KDM4E
SCHEMBL13942881 0.70 CYP19A1 (0.37) ALDH1A1HPGDSMN1; SMN2KDM4ENQO2
SCHEMBL23829578 0.67 HPGD (0.46) ALDH1A1CYP3A4HPGDBRPF1ATAD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114751905-A Novel pyridopyrimidine derivative compound, pharmaceutical composition thereof and use thereof 生物实验萨纽斯药物有限公司 2022-07-15 — — CN disclosed
US-10822333-B2 Pyridopyrimidines derivatives compounds BIOLAB SANUS FARMACEUTICA LTDA (BR) 2020-11-03 — — US disclosed
US-10822333-B2 Pyridopyrimidines derivatives compounds BIOLAB SANUS FARMACEUTICA LTDA (BR) 2020-11-03 — — US disclosed
US-20190218216-A1 PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS BIOLAB SANUS FARMACEUTICA LTDA (BR) 2019-07-18 — — US disclosed
US-20190218216-A1 PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS BIOLAB SANUS FARMACEUTICA LTDA (BR) 2019-07-18 — — US disclosed
US-10280162-B2 Pyridopyrimidines derivatives compounds BIOLAB SANUS FARMACEUTICA LTDA (BR) 2019-05-07 — — US disclosed
US-10280162-B2 Pyridopyrimidines derivatives compounds BIOLAB SANUS FARMACEUTICA LTDA (BR) 2019-05-07 — — US disclosed
EP-3191099-B1 DERIVATIVES OF PYRIDOPYRIMIDINES BIOLAB SANUS FARMACEUTICA LTDA (BR) 2018-11-14 — — EP disclosed
US-20180111926-A2 NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS BIOLAB SANUS FARMACEUTICA LTDA (BR) 2018-04-26 — — US disclosed
US-20180111926-A2 NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS BIOLAB SANUS FARMACEUTICA LTDA (BR) 2018-04-26 — — US disclosed
US-20160075702-A1 NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS BIOLAB SANUS FARMACEUTICA LTDA (BR) 2016-03-17 — — US disclosed
US-20160075702-A1 NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS BIOLAB SANUS FARMACEUTICA LTDA (BR) 2016-03-17 — — US disclosed
US-8198441-B2 Process for the preparation of novel pyridopyrazines as mTOR kinase inhibitors ASTRAZENECA AB (SE) 2012-06-12 — — US disclosed
US-20090318434-A1 COMPOSITION AND PROCESS - 356 ASTRAZENECA AB (SE) 2009-12-24 — — US disclosed
US-20090048374-A1 STABILIZER COMPOSITIONS FOR HALOGENATED POLYMERS WITH IMPROVED INITIAL COLOR AND IMPROVED COLOR MAINTENANCE BAERLOCHER GMBH (DE) 2009-02-19 — — US disclosed
EP-1996649-A1 STABILIZER COMPOSITIONS FOR HALOGENATED POLYMERS WITH IMPROVED INITIAL COLOR AND IMPROVED COLOR MAINTENANCE Baerlocher GmbH (DE) 2008-12-03 — — EP disclosed
WO-2007104379-A1 STABILIZER COMPOSITIONS FOR HALOGENATED POLYMERS WITH IMPROVED INITIAL COLOR AND IMPROVED COLOR MAINTENANCE BAERLOCHER GMBH (DE) 2007-09-20 — — WO disclosed
EP-0041479-B1 CHLORINE-CONTAINING THERMOPLASTIC POLYMERS STABILIZED WITH AMINO-THIOURACILS CIBA-GEIGY AG (CH) 1984-04-04 — — EP disclosed
US-4352903-A HEAT RESISTANT MOLDING MATERIALS CIBA-GEIGY CORPORATION (US) 1982-10-05 — — US disclosed
EP-0041479-A1 Chlorine-containing thermoplastic polymers stabilized with amino-thiouracils CIBA-GEIGY AG (CH) 1981-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180111926-A2 NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS PDE5A, PDE2A, PDE3A ALDH1A1 1755/4885CYP3A4 839/4885HPGD 224/4885
US-10280162-B2 Pyridopyrimidines derivatives compounds PDE5A, PDE2A, PDE3A ALDH1A1 1862/4885CYP3A4 899/4885HPGD 236/4885
US-20190218216-A1 PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS PDE5A, PDE2A, PDE3A ALDH1A1 1862/4885CYP3A4 899/4885HPGD 236/4885
US-20160075702-A1 NEW PYRIDOPYRIMIDINES DERIVATIVES COMPOUNDS PDE5A, PDE2A, PDE3A ALDH1A1 1755/4885CYP3A4 839/4885HPGD 224/4885
US-10822333-B2 Pyridopyrimidines derivatives compounds PDE5A, PDE2A, PDE3A ALDH1A1 1862/4885CYP3A4 899/4885HPGD 236/4885
US-20090318434-A1 COMPOSITION AND PROCESS - 356 FH, CS, SDHB ALDH1A1 879/4885CYP3A4 541/4885HPGD 473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.